BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34433663)

  • 1. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
    Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
    Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
    Robert M; Farese H; Miossec P
    Front Immunol; 2022; 13():820046. PubMed ID: 35265077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors.
    Tang F; Tie Y; Hong WQ; He X; Min L; Zhou Y; Luo Y; Chen SY; Yang JY; Shi HH; Wei XW; Tu CQ
    Ann Surg Oncol; 2021 Oct; 28(11):6453-6463. PubMed ID: 33748895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
    Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
    Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexidartinib: First Approval.
    Lamb YN
    Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
    Staals EL; Ferrari S; Donati DM; Palmerini E
    Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors.
    van IJzendoorn DGP; Matusiak M; Charville GW; Spierenburg G; Varma S; Colburg DRC; van de Sande MAJ; van Langevelde K; Mohler DG; Ganjoo KN; Bui NQ; Avedian RS; Bovée JVMG; Steffner R; West RB; van de Rijn M
    Clin Cancer Res; 2022 Nov; 28(22):4934-4946. PubMed ID: 36007098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.